Indeed, treatment of breast cancer and melanoma cell lines with the DNA methyltransferase inhibitor guadecitabine, alone or in combination with histone deacetylase (HDAC) inhibitor valproic acid, promoted loss of VCX2 promoter DNA methylation and induced VCX2 expression. The gene discussed is VCX2; the disease is breast carcinoma.